Trade Name (Agent): Epkinly™ (epcoritamab-bysp)
Sponsor: Genmab U.S.
Date of BT Designation Disclosure: 11/27/2023
Indication: Treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received 2 or more lines of systemic therapy.
Category: Cancer